Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity.
De Simone, C., Amerio, P., Amoruso, G., Bardazzi, F., Campanati, A., Conti, A., Gisondi, P., Gualdi, G., Guarneri, C., Leoni, L., Loconsole, F., Mazzotta, A., Musumeci, M., Piaserico, S., Potenza, C., Prestinari, F., Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?, <<EXPERT OPINION ON BIOLOGICAL THERAPY>>, 2013; 13 (12): 1673-1682. [doi:10.1517/14712598.2013.848194] [http://hdl.handle.net/10807/51735]
Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
De Simone, Clara;
2013
Abstract
Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
